3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Squamous Cell Carcinoma of Head and Neck
17
Head and Neck Neoplasms
10
Melanoma
9
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
6
Neoplasm Metastasis
6
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Stomach Neoplasms
4
Ovarian Neoplasms
4
Mouth Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Merkel Cell
4
Carcinoma, Hepatocellular
4
Pancreatic Neoplasms
3
Oropharyngeal Neoplasms
3
Laryngeal Neoplasms
3
Colonic Neoplasms
3
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Sarcoma
2
Recurrence
2
Prostatic Neoplasms
2
Kidney Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Carcinoma
2
Interventions
pembrolizumab
4
Radiotherapy
3
Riluzole
2
Ipilimumab
2
Drug Therapy
2
Counseling
2
Carboplatin
2
Bupropion
2
Blood Specimen Collection
2
vofatamab
1
utomilumab
1
trastuzumab deruxtecan
1
tocilizumab
1
spartalizumab
1
sargramostim
1
pazopanib
1
liposomal doxorubicin
1
ixabepilone
1
fostamatinib
1
fluoromisonidazole
1
erythromycin propionate-N-acetylcysteinate
1
cemiplimab
1
brodalumab
1
aldesleukin
1
Zinc Oxide
1
Varenicline
1
Topotecan
1
Tobacco Use Cessation Devices
1
Tissue Banks
1
Thiotepa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
cemiplimab
×
Head & Neck
×
Clear all
NCT06923761
2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2
Recruiting
300 enrolled